These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 11702603

  • 1. Special clinical concerns/problems in the management of MDS and secondary acute myeloid leukemias.
    Venugopal P, Manson S, Preisler HD.
    Cancer Treat Res; 2001; 108():257-65. PubMed ID: 11702603
    [No Abstract] [Full Text] [Related]

  • 2. Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia.
    Oosterveld M, de Witte T.
    Blood Rev; 2000 Dec; 14(4):182-9. PubMed ID: 11124106
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT).
    Trobaugh-Lotrario AD, Kletzel M, Quinones RR, McGavran L, Proytcheva MA, Hunger SP, Malcolm J, Schissel D, Hild E, Giller RH.
    Bone Marrow Transplant; 2005 Jan; 35(2):143-9. PubMed ID: 15558042
    [Abstract] [Full Text] [Related]

  • 5. [Therapy-related acute leukaemia and myelodysplastic syndrome].
    Díaz Beveridge R, Aparicio Urtasun J.
    An Med Interna; 2003 May; 20(5):257-68. PubMed ID: 12831302
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Autologous stem cell transplantation in myelodysplastic syndromes.
    de Witte T, Suciu S, Brand R, Muus P, Kröger N.
    Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
    [Abstract] [Full Text] [Related]

  • 10. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
    Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, Marsh J, Milligan D, Goldstone A, Hunter A, Khwaja A, Chopra R, Littlewood T, Peniket A, Parker A, Jackson G, Hale G, Cook M, Russell N, Mackinnon S.
    J Clin Oncol; 2005 Dec 20; 23(36):9387-93. PubMed ID: 16314618
    [Abstract] [Full Text] [Related]

  • 11. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun 20; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
    Knipp S, Hildebrand B, Kündgen A, Giagounidis A, Kobbe G, Haas R, Aul C, Gattermann N, Germing U.
    Cancer; 2007 Jul 15; 110(2):345-52. PubMed ID: 17559141
    [Abstract] [Full Text] [Related]

  • 14. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
    Matsouka P, Pagoni M, Zikos P, Giannakoulas N, Apostolidis I, Asprogeraka T, Arvanitopoulou E, Spanoudakis E, Kotsianidis I, Tsatalas K, Papaioannou M, Marinakis T, Skandali A, Viniou N, Yataganas X, Bakiri M.
    Ann Hematol; 2006 Apr 15; 85(4):250-6. PubMed ID: 16416114
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
    Oriol A, Ribera JM, Esteve J, Guàrdia R, Brunet S, Bueno J, Pedro C, Llorente A, Tormo M, Besalduch J, Sánchez JM, Batlle M, Vivancos P, Carreras E, Vilà JM, Julià A, Sierra J, Montserrat E, Feliu E, CETLAM AML-99.
    Haematologica; 2004 Jul 15; 89(7):791-800. PubMed ID: 15257930
    [Abstract] [Full Text] [Related]

  • 17. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes.
    Ballen KK, Antin JH.
    Hematol Oncol Clin North Am; 1993 Apr 15; 7(2):477-93. PubMed ID: 8468276
    [Abstract] [Full Text] [Related]

  • 18. A case of therapy-related acute myeloid leukemia associated with inv(16), with subsequent development of t(9;22).
    Kim M, Lim J, Kim Y, Han K, Kang CS, Kim HJ, Min WS.
    Leukemia; 2006 Apr 15; 20(4):746-8. PubMed ID: 16437154
    [No Abstract] [Full Text] [Related]

  • 19. Molecular characteristics therapy in AML.
    Radich GP.
    Clin Adv Hematol Oncol; 2009 Jun 15; 7(6):11-4. PubMed ID: 19645131
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.